BACKGROUND: Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant cancer syndrome, characterised by familial aggregation of HNPCC related cancers, germline mutations in mismatch repair genes, and/or microsatellite instability (MSI) in tumour tissue. AIM: To estimate the frequency of HNPCC among non-selected Danish patients with colorectal cancer (CRC), and to evaluate the value of MSI analysis as a pre-screen test. METHODS: This was a prospective population based study on consecutive CRC patients. A family history of malignancy was obtained and suspected HNPCC cases were screened for hMLH1/hMSH2 mutations and subjected to MSI analysis. Patients with germline mutations and/or those with Amsterdam criteria I or II families were categorised as HNPCC patients. RESULTS: Among 1328 eligible CRC patients, 1200 (90.4%) completed a questionnaire. A total of 1.7% (95% confidence interval (CI) 1.0-2.4) (20 cases) were categorised as HNPCC patients. Amsterdam criteria I or II were met in 18 cases (1.5%), and in another two cases (0.2%) pathogenic hMLH1/hMSH2 mutations were detected without fulfillment of the Amsterdam criteria I or II. Among 77 patients younger than 50 years of age, 11 cases (14.3%) were categorised as HNPCC. The Amsterdam criteria I or II were met in eight of 10 gene carriers (80%). The MSI-high phenotype was demonstrated in all 10 gene carriers. CONCLUSION: The frequency of HNPCC was approximately 1.7% among all CRC cases and 14.3% among patients younger than 50 years of age. MSI analysis is a reliable pre-screen test for hMLH1/hMSH2 mutations in families suspected of having HNPCC.
BACKGROUND:Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant cancer syndrome, characterised by familial aggregation of HNPCC related cancers, germline mutations in mismatch repair genes, and/or microsatellite instability (MSI) in tumour tissue. AIM: To estimate the frequency of HNPCC among non-selected Danish patients with colorectal cancer (CRC), and to evaluate the value of MSI analysis as a pre-screen test. METHODS: This was a prospective population based study on consecutive CRCpatients. A family history of malignancy was obtained and suspected HNPCC cases were screened for hMLH1/hMSH2 mutations and subjected to MSI analysis. Patients with germline mutations and/or those with Amsterdam criteria I or II families were categorised as HNPCCpatients. RESULTS: Among 1328 eligible CRCpatients, 1200 (90.4%) completed a questionnaire. A total of 1.7% (95% confidence interval (CI) 1.0-2.4) (20 cases) were categorised as HNPCCpatients. Amsterdam criteria I or II were met in 18 cases (1.5%), and in another two cases (0.2%) pathogenic hMLH1/hMSH2 mutations were detected without fulfillment of the Amsterdam criteria I or II. Among 77 patients younger than 50 years of age, 11 cases (14.3%) were categorised as HNPCC. The Amsterdam criteria I or II were met in eight of 10 gene carriers (80%). The MSI-high phenotype was demonstrated in all 10 gene carriers. CONCLUSION: The frequency of HNPCC was approximately 1.7% among all CRC cases and 14.3% among patients younger than 50 years of age. MSI analysis is a reliable pre-screen test for hMLH1/hMSH2 mutations in families suspected of having HNPCC.
Authors: J L Mary; T Bishop; R Kolodner; J R Lipford; M Kane; W Weber; J Torhorst; H Müller; M Spycher; R J Scott Journal: Hum Mol Genet Date: 1994-11 Impact factor: 6.150
Authors: C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom Journal: Nature Date: 1994-03-17 Impact factor: 49.962
Authors: Y Wu; M J Berends; R G Mensink; C Kempinga; R H Sijmons; A G van Der Zee; H Hollema; J H Kleibeuker; C H Buys; R M Hofstra Journal: Am J Hum Genet Date: 1999-11 Impact factor: 11.025
Authors: A Viel; M Genuardi; E Capozzi; F Leonardi; A Bellacosa; M Paravatou-Petsotas; M G Pomponi; M Fornasarig; A Percesepe; L Roncucci; M G Tamassia; P Benatti; M Ponz de Leon; A Valenti; M Covino; M Anti; M Foletto; M Boiocchi; G Neri Journal: Genes Chromosomes Cancer Date: 1997-01 Impact factor: 5.006
Authors: C Brassett; J A Joyce; N J Froggatt; G Williams; D Furniss; S Walsh; R Miller; D G Evans; E R Maher Journal: J Med Genet Date: 1996-12 Impact factor: 6.318
Authors: M G Dunlop; S M Farrington; A D Carothers; A H Wyllie; L Sharp; J Burn; B Liu; K W Kinzler; B Vogelstein Journal: Hum Mol Genet Date: 1997-01 Impact factor: 6.150
Authors: B Liu; R Parsons; N Papadopoulos; N C Nicolaides; H T Lynch; P Watson; J R Jass; M Dunlop; A Wyllie; P Peltomäki; A de la Chapelle; S R Hamilton; B Vogelstein; K W Kinzler Journal: Nat Med Date: 1996-02 Impact factor: 53.440
Authors: S R Hamilton; B Liu; R E Parsons; N Papadopoulos; J Jen; S M Powell; A J Krush; T Berk; Z Cohen; B Tetu Journal: N Engl J Med Date: 1995-03-30 Impact factor: 91.245
Authors: N C Nicolaides; N Papadopoulos; B Liu; Y F Wei; K C Carter; S M Ruben; C A Rosen; W A Haseltine; R D Fleischmann; C M Fraser Journal: Nature Date: 1994-09-01 Impact factor: 49.962
Authors: E Urso; M Agostini; S Pucciarelli; M Rugge; R Bertorelle; I Maretto; C Bedin; E D'Angelo; C Mescoli; M Zorzi; A Viel; G Bruttocao; B Ferraro; F Erroi; P Contin; G L De Salvo; D Nitti Journal: Tumour Biol Date: 2012-01-26
Authors: M Ponz de Leon; P Benatti; F Borghi; M Pedroni; A Scarselli; C Di Gregorio; L Losi; A Viel; M Genuardi; G Abbati; G Rossi; M Menigatti; I Lamberti; G Ponti; L Roncucci Journal: Gut Date: 2004-01 Impact factor: 23.059
Authors: Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels Journal: Fam Cancer Date: 2008-06-20 Impact factor: 2.375
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506